MedTrace Logo

Rituximab and DexaBEAM as Salvage Therapy for Relapsed Lymphoma

NCT02099292 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2014-03-28

No results posted yet for this study

Summary

The investigator prospectively evaluated the combination of Rituximab and Dexa-BEAM (dexamethasone, carmustine, etoposide, cytarabine, melphalan) followed by high dose therapy in patients with relapsed/refractory aggressive and indolent lymphoma.

Conditions

  • Relapsed Non-Hodgkin-Lymphoma

Interventions

DRUG

Rituximab and DexaBEAM

combination treatment

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Klinikum Frankfurt Höchst

    collaborator OTHER

  • Georg Hess, MD

    lead OTHER

Principal Investigators

  • Georg Hess, MD · Johannes Gutenberg University Mainz

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-05-31
Primary Completion
2005-05-31
Completion
2014-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02099292 on ClinicalTrials.gov